BioXcel Therapeutics (BTAI) Cash & Equivalents (2017 - 2026)

BioXcel Therapeutics' Cash & Equivalents history runs 10 years deep, the most recent figure standing at $17.2 million for Q1 2026.

• In Q1 2026, Cash & Equivalents fell 44.6% year-over-year to $17.2 million; the TTM figure through Mar 2026 stood at $17.2 million (down 44.6% YoY), while the FY2025 annual figure was $28.4 million, down 4.82% from the prior year.
• Cash & Equivalents for Q1 2026 stood at $17.2 million, down from $28.4 million in the prior quarter.
• The five-year high for Cash & Equivalents was $233.5 million in Q2 2022, with the low at $17.2 million in Q1 2026.
• The 5-year median for Cash & Equivalents is $65.2 million (2023), against an average of $96.4 million.
• The sharpest annual moves came in 2022 and 2025: Cash & Equivalents grew 3.31% in 2022, then slumped 69.02% in 2025.
• BioXcel Therapeutics' Cash & Equivalents stood at $193.7 million in 2022, then plunged by 66.33% to $65.2 million in 2023, then sank by 54.23% to $29.9 million in 2024, then retreated by 4.82% to $28.4 million in 2025, then sank by 39.54% to $17.2 million in 2026.
• Business Quant data shows BTAI's Cash & Equivalents at $17.2 million in Q1 2026, $28.4 million in Q4 2025, and $36.2 million in Q3 2025.